本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日（以下简称"本 报告期""报告期"）。 证券代码：300970 证券简称：华绿生物 公告编号：2026-004 江苏华绿生物科技集团股份有限公司 2025 年度业绩预告 （二）业绩预告情况：亏损 扭亏为盈 同向上升 同向下降 | 项 目 | 本报告期 | 上年同期 | | | --- | --- | --- | --- | | 营业收入 | 120,000.00～140,000.00 万元 | 103,211.16 | 万元 | | | 比上年同期增长：16.27%～35.64% | | | | 归属于上市 | 盈利：10,000.00～13,000.00 万元 | 亏损：4,756.56 | 万元 | | 净利润 | 比上年同期上升：310.24%～373.31% | | | | 归属于上市 公司股东扣 除非经常性 | 万元 盈利：10,000.00～13,000.00 | 亏损：4,848.39 | 万 ...

Core Viewpoint - The company, Hualv Biotechnology, plans to acquire 100% equity of Queshan Huayuan Biotechnology Co., Ltd. from the Queshan County Finance Bureau, aiming to secure long-term operational stability and enhance investment outcomes in Queshan County [1] Group 1: Acquisition Details - The acquisition will be based on the total investment amount of approximately 239 million yuan, which includes main engineering, ancillary works, equipment, and supervision fees [1] - The payment for the acquisition will be made in installments: 50% within five working days after signing the formal equity transfer agreement, 40% within ten working days after completing the industrial and commercial change registration, and the remaining 10% as a performance guarantee within twelve months after the equity transfer [1] Group 2: Project Background - Queshan Huayuan is a platform company designated by the Queshan County People's Government and is wholly owned by the Queshan County Finance Bureau [1] - The first mushroom factory constructed by Queshan Huayuan has been completed and handed over to Hualv Biotechnology, with the factory's operational status meeting the company's expectations [1]

Core Viewpoint - The company, Hualv Biotechnology, is advancing its investment project in Queshan County, with plans to solidify its partnership with local government through a share acquisition framework agreement [1] Group 1: Project Overview - The company announced plans to establish a subsidiary in Queshan County, covering an area of approximately 500 acres with a total investment of around RMB 500 million [1] - The initial phase includes the construction of two edible mushroom factories, with land and facilities funded by the government [1] Group 2: Current Status and Future Plans - The first factory in Queshan County has been completed and is operational, achieving expected benefits [1] - To ensure long-term stability and reduce project risks, the company intends to sign a share acquisition framework agreement with relevant parties [1] Group 3: Strategic Agreements - The framework agreement aims to outline the future acquisition of 100% equity of a target company held by the Queshan Finance Bureau, including overall arrangements, prerequisites, and key terms [1] - This agreement is designed to enhance investment confidence and solidify existing cooperation outcomes [1]

Core Viewpoint - The company plans to sign an investment agreement with the People's Government of Que County to establish a new factory for the production of deer antler mushrooms, with a total investment of approximately RMB 300 million [1] Group 1: Project Details - The new factory will have an annual production capacity of 50,000 tons of deer antler mushrooms [1] - The project will cover an area of approximately 200 acres [1] - The investment proposal was approved during the company's fifth board meeting on January 16, 2026 [1] Group 2: Regulatory Compliance - The investment does not require submission for shareholder approval according to the Shenzhen Stock Exchange's Growth Enterprise Market listing rules and the company's articles of association [1]

证券代码：300970 证券简称：华绿生物 公告编号：2026-001 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届董事会第 十七次会议于 2026 年 1 月 16 日以现场和通讯相结合的方式在公司二楼会议室召 开，会议通知于 2026 年 1 月 12 日以通讯方式向全体董事发出。会议由董事长余 养朝先生召集并主持，会议应出席董事 9 人，实际出席董事 9 人，公司高级管理 人员列席了本次会议。本次董事会的召开符合《中华人民共和国公司法》等有关 法律、行政法规等规范性文件及《公司章程》的规定。 二、董事会审议情况 经与会董事认真审议，形成如下决议： （一）审议通过了《关于拟签订<股权收购框架协议>的议案》 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于拟签订<股权收购框架协议>的公告》（公告编号：2026-002）。 江苏华绿生物科技集团股份有限公司 第五届董事会第十七次会议决议公告 具体内容详见公司同日于巨潮资讯网（ht ...

关于拟签订《股权收购框架协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 证券代码：300970 证券简称：华绿生物 公告编号：2026-002 江苏华绿生物科技集团股份有限公司 特别提示： 1、江苏华绿生物科技集团股份有限公司（以下简称"公司"）于 2022 年 11 月 23 日披露了《关于签署〈投资协议〉并拟在确山县设立子公司的公告》（公 告编号：2022-064）。根据原计划，项目占地面积约 500 亩，预计总投资约人民 币 5 亿元，初期拟建设两个食用菌工厂。相关土地、大棚房及附属设施由政府方 出资购置或建设，待建设完成并取得合法手续后租赁给公司使用。租赁期满后， 若公司符合约定条件，可享有优先购买权。 目前，公司在确山县投资的第一个工厂已建成投产并实现预期效益。为保证 项目长期稳定，减少项目变动风险，公司拟与相关方签订《股权收购框架协议》， 明确收购政府投资资产的核心安排，以进一步巩固现有合作成果，增强当地产业 发展信心。 2、根据《深圳证券交易所创业板股票上市规则》等规范性文件及《江苏华 绿生物科技集团股份有限公司章程》（以下简称" ...

证券代码：300970 证券简称：华绿生物 公告编号：2026-003 江苏华绿生物科技集团股份有限公司 关于拟签订《投资协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、《投资协议》中关于项目投资金额、用地面积等指标均为预估数值，并 不代表对投资者的承诺。 2、根据《深圳证券交易所创业板股票上市规则》等规范性文件及《江苏华 绿生物科技集团股份有限公司章程》（以下简称"《公司章程》"）规定，本事 项无需提交公司股东会审议。 3、本次投资不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 4、公司于 2022 年 11 月 23 日在巨潮资讯网（http://www.cninfo.com.cn）披 露了《关于签署<投资协议>并拟在确山县设立子公司的公告》（公告编号： 2022-064），项目规划占地面积约 500 亩，项目预计总投资约人民币 5 亿元，初 期计划建设两个食用菌工厂，项目的土地、大棚房及其附属设施由政府方出资购 买或者建设，在约定时间完成建设并办理合法合规手续后租赁给公司。现第一个 工厂（金 ...

Market Overview - The planting industry sector declined by 0.42% on January 14, with Shennong Agricultural leading the decline [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Individual Stock Performance - Hualu Biological (300970) saw a price increase of 4.06%, closing at 22.53 with a trading volume of 108,000 shares and a transaction value of 236 million yuan [1] - Hainan Rubber (601118) increased by 1.18%, closing at 5.98 with a trading volume of 1,009,400 shares and a transaction value of 609 million yuan [1] - Shennong Agricultural (300189) experienced a significant decline of 3.77%, closing at 6.89 with a trading volume of 2,088,600 shares and a transaction value of 1.454 billion yuan [2] Capital Flow Analysis - The planting industry sector experienced a net outflow of 243 million yuan from main funds, while retail investors saw a net inflow of 240 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Hualu Biological and Hainan Rubber, while Shennong Agricultural faced significant outflows [3]

Group 1 - The core point of the news is that Hualu Bio has seen a stock price increase of 5.08%, reaching 22.75 CNY per share, with a trading volume of 190 million CNY and a turnover rate of 9.17%, resulting in a total market capitalization of 2.789 billion CNY [1] - Hualu Bio, established on June 8, 2010, and listed on April 12, 2021, specializes in the research, industrial cultivation, and sales of edible mushrooms, with revenue composition of 70.73% from enoki mushrooms and 29.27% from king oyster mushrooms [1] Group 2 - Among the top ten circulating shareholders of Hualu Bio, the Noan Multi-Strategy Mixed A Fund (320016) has recently entered the list, holding 1.0993 million shares, which accounts for 1.17% of the circulating shares, with an estimated floating profit of approximately 1.2092 million CNY [2] - The Noan Multi-Strategy Mixed A Fund was established on August 9, 2011, with a current scale of 1.855 billion CNY, achieving a year-to-date return of 5.21%, ranking 2743 out of 8838 in its category, and an annual return of 88.18%, ranking 316 out of 8089 [2] Group 3 - The fund manager of Noan Multi-Strategy Mixed A is Kong Xianzheng, who has been in the position for 5 years and 50 days, managing a total fund asset size of 5.608 billion CNY, with the best fund return during his tenure being 93.39% and the worst being -16.74% [3]

Group 1 - The core point of the article highlights the recent performance of Hualu Bio, which saw a 5.07% increase in stock price, reaching 21.54 CNY per share, with a trading volume of 1.03 billion CNY and a turnover rate of 5.16%, resulting in a total market capitalization of 2.641 billion CNY [1] - Hualu Bio, established on June 8, 2010, and listed on April 12, 2021, specializes in the research, industrial cultivation, and sales of edible mushrooms, with its main revenue sources being enoki mushrooms (70.73%) and king oyster mushrooms (29.27%) [1] Group 2 - From the perspective of fund holdings, Huatai-PineBridge Fund has a significant position in Hualu Bio, with its Huatai-PineBridge Quantitative Alpha A fund holding 90,400 shares, accounting for 0.5% of the fund's net value, making it the fifth-largest holding [2] - The Huatai-PineBridge Quantitative Alpha A fund, established on September 26, 2017, has a current size of 203 million CNY, with a year-to-date return of 5.9% and a one-year return of 39.99%, ranking 2766 out of 8836 and 3496 out of 8091 respectively [2] - The fund managers, Sheng Hao and Kong Lingye, have tenures of 10 years and 3 years respectively, with Sheng managing assets totaling 4.417 billion CNY and achieving a best return of 138.1% during his tenure [2]